NATIONAL INSTITUTES OF HEALTH
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System
Not Applicable
Not yet recruiting
- Conditions
- Locally Recurrent Skin Squamous Cell CarcinomaMetastatic Skin Squamous Cell Carcinoma
- Interventions
- Drug: Amivantamab and Recombinant Human HyaluronidaseProcedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Magnetic Resonance Imaging
- First Posted Date
- 2025-06-29
- Last Posted Date
- 2025-06-29
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 86
- Registration Number
- NCT07042295
Exploring How to Adapt an Evidence-Based Mindful Self-Compassion Program for Young Adults With Li-Fraumeni Syndrome
Recruiting
- Conditions
- Li-Fraumeni Syndrome
- First Posted Date
- 2025-06-24
- Last Posted Date
- 2025-06-29
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 20
- Registration Number
- NCT07032922
- Locations
- πΊπΈ
NCI Shady Grove Campus, Rockville, Maryland, United States
Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants
Not yet recruiting
- Conditions
- Germline MutationMyelodysplastic SyndromesAcute Myeloid Leukemia
- First Posted Date
- 2025-06-13
- Last Posted Date
- 2025-07-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 510
- Registration Number
- NCT07019155
- Locations
- πΊπΈ
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
Phase 1
Not yet recruiting
- Conditions
- Acute Myeloid Leukemia Post Cytotoxic TherapyRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Imaging ProcedureProcedure: Lumbar Puncture
- First Posted Date
- 2025-06-10
- Last Posted Date
- 2025-06-10
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 47
- Registration Number
- NCT07012044
Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation
Phase 1
Not yet recruiting
- Conditions
- Locally Advanced Lung Non-Small Cell CarcinomaMetastatic Lung Non-Small Cell CarcinomaStage III Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8
- Interventions
- Procedure: Biopsy ProcedureProcedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Echocardiography TestProcedure: Magnetic Resonance ImagingProcedure: Multigated Acquisition Scan
- First Posted Date
- 2025-06-10
- Last Posted Date
- 2025-06-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 37
- Registration Number
- NCT07012031
Clinical Genetics Branch Eligibility Screening Survey
Not yet recruiting
- Conditions
- MelanomaLi-Fraumeni SyndromePulmonary BlastomaChordomaCongenital Bone Marrow Failure SyndromesCostello SyndromeFanconi AnemiaCFC Syndrome (CFCS)Legius SyndromeRASopathies
- First Posted Date
- 2025-06-05
- Last Posted Date
- 2025-07-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1000
- Registration Number
- NCT07005297
- Locations
- πΊπΈ
National Cancer Institute, Rockville, Maryland, United States
Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy
Phase 2
Not yet recruiting
- Conditions
- Recurrent Mantle Cell LymphomaRefractory Mantle Cell Lymphoma
- Interventions
- Procedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Positron Emission Tomography
- First Posted Date
- 2025-06-04
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 20
- Registration Number
- NCT07003295
A Study to Evaluate Multicancer Detection (MCD) Tests and Their Impact on Participant Health and Cancer Screening, The Vanguard Study
Not Applicable
Not yet recruiting
- Conditions
- Bladder CarcinomaBreast CarcinomaColorectal CarcinomaEsophageal CarcinomaGastric CarcinomaLiver CarcinomaLung CarcinomaMalignant Solid NeoplasmOvarian CarcinomaPancreatic Carcinoma
- First Posted Date
- 2025-05-30
- Last Posted Date
- 2025-06-10
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 24000
- Registration Number
- NCT06995898
Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma
Phase 1
Not yet recruiting
- Conditions
- Neuroblastoma
- Interventions
- First Posted Date
- 2025-05-30
- Last Posted Date
- 2025-07-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 34
- Registration Number
- NCT06995872
- Locations
- πΊπΈ
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer
Phase 1
Not yet recruiting
- Conditions
- Thyroid Cancer
- Interventions
- First Posted Date
- 2025-05-28
- Last Posted Date
- 2025-07-03
- Target Recruit Count
- 18
- Registration Number
- NCT06991738
- Locations
- πΊπΈ
National Institutes of Health Clinical Center, Bethesda, Maryland, United States